Contineum Therapeutics, Inc.
CTNM
$14.19
-$1.11-7.26%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 26.22% | 17.52% | 12.73% | 27.81% | 31.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.65% | -6.66% | 0.40% | 15.09% | 63.58% |
| Operating Income | 2.65% | 6.66% | -0.40% | -15.09% | -63.58% |
| Income Before Tax | 5.52% | 9.59% | -4.06% | -24.59% | -78.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 5.52% | 9.59% | -4.06% | -24.59% | -78.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.52% | 9.59% | -4.06% | -24.59% | -78.04% |
| EBIT | 2.65% | 6.66% | -0.40% | -15.09% | -63.58% |
| EBITDA | 2.97% | 6.72% | -0.34% | -15.02% | -63.75% |
| EPS Basic | 34.69% | 37.36% | 12.96% | -14.04% | -60.59% |
| Normalized Basic EPS | 34.69% | 37.35% | 12.96% | -14.03% | -60.56% |
| EPS Diluted | 34.69% | 37.36% | 12.96% | -14.04% | -60.59% |
| Normalized Diluted EPS | 34.69% | 37.35% | 12.96% | -14.03% | -60.56% |
| Average Basic Shares Outstanding | 44.69% | 44.34% | 19.55% | 9.27% | 10.88% |
| Average Diluted Shares Outstanding | 44.69% | 44.34% | 19.55% | 9.27% | 10.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |